Case Details
- Citation: [2022] SGHC 75
- Title: Mytsyk, Viktoriia v Med Travel Pte Ltd and another
- Court: High Court of the Republic of Singapore (General Division)
- Originating Summons No: OS 987 of 2021
- Date of Judgment: 31 March 2022
- Date of Hearing(s): 13 January 2022; 25 February 2022
- Judge: Mavis Chionh Sze Chyi J
- Plaintiff/Applicant: Mytsyk, Viktoriia (“Ms Mytsyk”)
- Defendants/Respondents: (1) Med Travel Pte Ltd (“Med Travel”) (2) Amunugama Anushka Bandara (“Mr Anushka”)
- Legal Area: Companies — Statutory derivative action
- Statutes Referenced: Companies Act (Cap 50, 2006 Rev Ed), in particular s 216A (including s 216A(3)(b) and (c))
- Judgment Length: 49 pages; 15,748 words
- Procedural Posture: Application for leave under s 216A of the Companies Act to bring a derivative action in the name and on behalf of the company against a director
- Representation: Ms Mytsyk represented by counsel; Mr Anushka acted in person
Summary
In Mytsyk, Viktoriia v Med Travel Pte Ltd and another [2022] SGHC 75, the High Court considered an application by a shareholder to obtain leave under s 216A of the Companies Act to commence a statutory derivative action against a director. The proposed defendant, Mr Anushka, was alleged to have breached his director’s duties to Med Travel in a range of ways, including misappropriation of funds, forgery of documents, causing the company to incur unaffordable debt through a property purchase, diversion of income, prevention of business, misuse of company funds for personal expenses, and negligence leading to GST penalties.
The court’s analysis focused on two gatekeeping requirements under s 216A(3): first, whether the applicant satisfied the “good faith” requirement (s 216A(3)(b)); and second, whether the intended derivative action “appears prima facie to be in the interests of the company” (s 216A(3)(c)). The court also addressed preliminary objections to the applicant’s locus standi to bring the application.
Ultimately, the court granted leave (or, as reflected in the judgment’s conclusion and final observations) after finding that the statutory prerequisites were met. The decision is significant for practitioners because it illustrates how the court evaluates competing narratives in family-and-control disputes, and how it applies the statutory threshold without turning the leave stage into a full trial on disputed facts.
What Were the Facts of This Case?
Ms Mytsyk and Mr Anushka were previously married and lived together for several years with children. Their relationship deteriorated, and Ms Mytsyk commenced divorce proceedings in August 2019. Shortly thereafter, she also commenced a civil suit, HC/S 1247/2019 (“S 1247”), against Mr Anushka and Med Travel. In S 1247, Ms Mytsyk’s co-plaintiffs included her father, Mr Hryhorii Liaskovskyi (“Mr Liaskovskyi”), and a company, Health & Help Pte Ltd (“Health & Help”), in which Ms Mytsyk was the sole shareholder and director on record. The relief sought in S 1247 included declarations that Mr Liaskovskyi was the true legal and beneficial owner of both Med Travel and Health & Help.
Med Travel was incorporated on 5 June 2012 and, at incorporation, Mr Anushka was its sole shareholder and director on record. On 20 November 2013, Mr Anushka transferred 50% of Med Travel’s shares to Mr Liaskovskyi. On 13 June 2016, Mr Liaskovskyi transferred that 50% shareholding to Ms Mytsyk. Ms Mytsyk was appointed a director of Med Travel on 7 June 2018. While these documentary events were not denied, the parties’ competing explanations were central to the dispute: Ms Mytsyk alleged that Mr Anushka acted merely as a “nominee shareholder and director” and that he forged signatures on share transfer documents and on documents relating to her appointment as director (although she later took the position that she had consented to and/or ratified her appointment).
Mr Anushka, by contrast, denied forgery and advanced a “Family Business” narrative. He claimed that Med Travel and Health & Help formed part of a family business jointly owned and managed by him and Ms Mytsyk, supported by what he described as a “Mutual Understanding” governing how the companies were run and how income and family expenses were handled. Ms Mytsyk denied the existence of such a family business arrangement and denied that she and Mr Anushka jointly owned and managed the companies pursuant to any mutual understanding.
Against this background, Ms Mytsyk brought the present application (OS 987/2021) under s 216A for leave to bring a statutory derivative action in the name and on behalf of Med Travel against Mr Anushka. Her allegations of breaches of director’s duties were broad and detailed. She alleged, among other things, that Mr Anushka misappropriated company funds by withdrawing approximately $477,000 from Med Travel’s bank accounts around 1 October 2019; forged “financial documents”; unlawfully caused Med Travel to incur unaffordable debt by purchasing a property at Novena Royal Square (“the Property”) despite insufficient funds to service the financing; diverted income due to Med Travel to his own company A B Capital Pte Ltd; unlawfully prevented Med Travel from carrying on business; misused company funds for personal expenses (including legal fees in the divorce proceedings and unauthorised transportation costs); and negligently caused Med Travel to incur GST penalties due to late GST submissions.
What Were the Key Legal Issues?
The first key legal issue was whether Ms Mytsyk had locus standi to bring the application for leave under s 216A. Mr Anushka argued that she did not fall within the statutory definition of a “complainant” in s 216A(1), and that she failed to identify the capacity in which she was bringing the application. He further contended that she could not show standing as a shareholder under s 216(1)(a) of the Companies Act, nor that she was a “proper person” under s 216(1)(c).
The second key issue concerned the statutory gatekeeping requirements under s 216A(3). Specifically, the court had to determine whether Ms Mytsyk satisfied the “good faith” requirement in s 216A(3)(b), including whether the application was brought honestly and for the proper purpose of enforcing the company’s rights rather than for collateral ends. Closely related was the question whether the intended derivative action “appears prima facie to be in the interests of the company” under s 216A(3)(c). This required the court to assess, at a preliminary stage, whether the allegations and proposed relief had a sufficient connection to the company’s interests.
Finally, the court had to consider how to treat the existence of the parallel suit S 1247 and the broader family dispute. In particular, the court needed to decide whether the derivative action was being pursued as a tactical extension of the divorce and related litigation, or whether it genuinely sought to address alleged wrongdoing by a director in relation to the company.
How Did the Court Analyse the Issues?
On locus standi, the court rejected the submission that Ms Mytsyk had failed to identify her capacity. The judge observed that it was not accurate to say she had not stated the basis for bringing the application. The court treated the statutory standing requirements as satisfied on the materials before it, emphasising that the leave stage is designed to enable a complainant to seek enforcement of company rights where the statutory threshold is met, rather than to impose overly technical barriers that would defeat the purpose of the derivative action regime.
The court then turned to the “good faith” requirement under s 216A(3)(b). This was the central battleground. Mr Anushka argued that Ms Mytsyk was bringing the derivative action for a collateral purpose—essentially to advance her position in the broader dispute, including the declarations sought in S 1247 about beneficial ownership and control. The court’s approach was to examine whether the evidence and allegations suggested that the application was genuinely directed to the company’s interests, or whether it was being used as leverage in a personal dispute.
In analysing good faith, the court reviewed the specific allegations made by Ms Mytsyk. It considered the nature of each alleged breach of duty and whether, on the face of the pleadings and affidavits, the claims were plausibly connected to harm to Med Travel. The allegations included: (a) misappropriation of funds; (b) forgery of share transfer and financial documents; (c) causing the company to purchase the Property despite inability to service the mortgage; (d) diversion of income to Mr Anushka’s own company; (e) preventing the company from carrying on business; (f) misuse of company funds for personal expenses; and (g) negligence resulting in GST penalties. The court also considered the additional detail that the mortgagee bank had granted overdraft facilities and that Mr Anushka allegedly drew on these facilities to meet mortgage payments, leaving Med Travel overdrawn and at risk of further debt.
Importantly, the court did not treat the leave application as a full merits trial. Instead, it assessed whether the applicant’s case, if taken at face value for the purpose of the statutory threshold, was consistent with enforcement of the company’s rights. On the collateral purpose argument, the court examined the relationship between the derivative action and the dispute in S 1247. While the parallel proceedings were relevant context, the court focused on whether the derivative action sought relief that would benefit the company (for example, recovery of misappropriated funds, rectification of losses caused by unauthorised diversion, and accountability for breaches of director’s duties) rather than merely serving as a vehicle for personal vindication.
The court also addressed the “prima facie interests of the company” requirement under s 216A(3)(c). It considered whether the proposed claims, if established, would likely result in recoveries or other remedies that would be beneficial to Med Travel. The judge’s reasoning reflected the statutory design: the court must be satisfied that there is a sufficient prima facie basis to conclude that the derivative action is not frivolous, vexatious, or purely opportunistic. In this case, the breadth and specificity of the allegations—particularly those involving alleged diversion of income and misappropriation of funds—supported the conclusion that the action could plausibly be in the company’s interests.
In reaching its conclusions, the court balanced the seriousness of the allegations against the need to avoid prejudging disputed facts. It also considered the applicant’s conduct and the coherence of her narrative with the relief sought. The court’s analysis of good faith and prima facie company interests demonstrates that the statutory derivative action regime is meant to provide a mechanism for minority or complainant shareholders to pursue claims where internal enforcement may be compromised, while still protecting directors and companies from unmeritorious litigation.
What Was the Outcome?
The High Court granted leave under s 216A for Ms Mytsyk to bring the intended statutory derivative action in the name and on behalf of Med Travel against Mr Anushka. The practical effect is that the derivative action could proceed, subject to the procedural steps required to commence the action and to comply with any directions made by the court.
The decision also clarifies that, at the leave stage, the court will scrutinise whether the application is brought in good faith and whether it appears prima facie to serve the company’s interests, but it will not require the applicant to conclusively prove disputed wrongdoing. This makes the leave stage a meaningful filter, while still allowing potentially meritorious claims to be litigated on evidence.
Why Does This Case Matter?
Mytsyk is a useful authority for understanding how Singapore courts apply the statutory derivative action framework under the Companies Act, particularly the twin requirements in s 216A(3)(b) and (c). For practitioners, the case demonstrates that the court will engage with arguments about collateral purpose and will examine whether the derivative action is genuinely directed to enforcing the company’s rights rather than being a proxy for personal disputes.
The decision is also instructive in contexts where corporate wrongdoing allegations are intertwined with family or relationship breakdowns and parallel litigation. The court’s approach shows that the existence of other proceedings does not automatically undermine good faith. Instead, the court looks at the substance of the derivative claims and the relief sought, and whether the claims have a plausible connection to harm suffered by the company.
From a litigation strategy perspective, the case highlights the importance of presenting a coherent evidential narrative at the leave stage. Applicants should clearly articulate their standing, address good faith concerns proactively, and explain why the proposed action is in the company’s interests. Conversely, respondents seeking to resist leave should focus on concrete indicators of collateral purpose or lack of prima facie company benefit, rather than relying solely on the existence of broader disputes.
Legislation Referenced
- Companies Act (Cap 50, 2006 Rev Ed), in particular s 216A (including s 216A(3)(b) and s 216A(3)(c))
- Companies Act (Cap 50, 2006 Rev Ed), s 216 (definitions of “complainant” and “proper person” as relevant to the derivative action framework)
Cases Cited
- [2014] SGHC 147
- [2015] SGHC 14523
- [2019] SGHC 180
- [2022] SGHC 75
Source Documents
This article analyses [2022] SGHC 75 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the full judgment for the Court's complete reasoning.